التداخل بين دوتاستيريد وتامسولوسين وفاردينافيل

Clinical pharmacology studies have been conducted with co-administration of vardenafil with alfuzosin, terazosin or tamsulosin. [See Dosage and Administration (2.4) , Warnings and Precautions (5.6) , and Clinical Pharmacology (12.2) .] Antihypertensives: Vardenafil hydrochloride tablets may add to the blood pressure lowering effects of antihypertensive agents.

Alpha-Blockers : Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Alpha-Blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Consideration should be given to the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.

Exercise caution with concomitant use of phosphodiesterase-5 (PDE-5) inhibitors, as this may increase the risk of hypotension.

Phosphodiesterase-5 (PDE-5) Inhibitors Caution is advised when alpha-adrenergic–antagonist-containing products, including JALYN, are coadministered with PDE-5 inhibitors.

Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure.